Xenon Q3 2024 net loss $62.8M; X-TOLE2 topline data expected H2 2025; COO appointed

Xenon Pharmaceuticals Inc.

2024-Q3 EPS reported -$2.17

Net loss of $62.8M for Q3 2024, compared to $48.5M in Q3 2023; R&D expenses rose to $57.0M.
Cash and marketable securities $803.3M as of Sep 30, 2024; cash runway expected into 2027.
Phase 3 X-TOLE2 focal onset seizure study topline data anticipated in H2 2025.
Phase 3 MDD study X-NOVA2 expected to initiate by end of 2024.
Appointed Matt Ronsheim as COO, new senior executive; early-stage pipeline targeting multiple INDs in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.